2020 日本专家共识:抑郁症的药物治疗

2020-01-28 国外精神科相关专家小组(统称) J Affect Disord. 2020 Jan 28;266:626-632.

2020年1月,日本临床神经精神药理学学会(JSCNP)发布了抑郁症的药物治疗专家共识,真实世界抑郁症治疗的临床相关问题并没总被常规治疗指南所涉及,日本临床神经精神药理学学会(JSCNP)专家组对23种抑郁症临床治疗情况的治疗方案进行评估,形成专家共识。

中文标题:

2020 日本专家共识:抑郁症的药物治疗

英文标题:

Pharmacological management of depression: Japanese expert consensus.

发布日期:

2020-01-28

简要介绍:

2020年1月,日本临床神经精神药理学学会(JSCNP)发布了抑郁症的药物治疗专家共识,真实世界抑郁症治疗的临床相关问题并没总被常规治疗指南所涉及,日本临床神经精神药理学学会(JSCNP)专家组对23种抑郁症临床治疗情况的治疗方案进行评估,形成专家共识。

 

拓展指南:抑郁症相关指南:

有关抑郁症更多指南

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 日本专家共识:抑郁症的药物治疗.pdf), AttachmentFileName(sort=100, fileName=2020 日本专家共识:抑郁症的药物治疗)] GetToolGuiderByIdResponse(projectId=1, id=2aa881c00186e2bb, title=2020 日本专家共识:抑郁症的药物治疗, enTitle=Pharmacological management of depression: Japanese expert consensus., guiderFrom=J Affect Disord. 2020 Jan 28;266:626-632., authorId=null, author=, summary=2020年1月,日本临床神经精神药理学学会(JSCNP)发布了抑郁症的药物治疗专家共识,真实世界抑郁症治疗的临床相关问题并没总被常规治疗指南所涉及,日本临床神经精神药理学学会(JSCNP)专家组对23种抑郁症临床治疗情况的治疗方案进行评估,形成专家共识。 , cover=, journalId=null, articlesId=null, associationId=1320, associationName=国外精神科相关专家小组(统称), associationIntro=, copyright=0, guiderPublishedTime=Tue Jan 28 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<p>2020年1月,日本临床神经精神药理学学会(JSCNP)发布了抑郁症的药物治疗专家共识,真实世界抑郁症治疗的临床相关问题并没总被常规治疗指南所涉及,日本临床神经精神药理学学会(JSCNP)专家组对23种抑郁症临床治疗情况的治疗方案进行评估,形成专家共识。</p> <p>&nbsp;</p> <p>拓展指南:<strong>与<span style="color: red;">抑郁症</span>相关指南:</strong></p> <ul> <ul> <li><a title="2019 ISNPR实践指南:应用Omega-3脂肪酸治疗抑郁症" href="https://www.medsci.cn/guideline/show_article.do?id=f34111c001e899f4" target="_blank" rel="noopener">2019 ISNPR实践指南:应用Omega-3脂肪酸治疗抑郁症</a></li> <li><a title="2019 临床实践指南:抑郁症与特定精神疾病共病的管理" href="https://www.medsci.cn/guideline/show_article.do?id=fbc051c001698e08" target="_blank" rel="noopener">2019 临床实践指南:抑郁症与特定精神疾病共病的管理</a></li> <li><a title="阿戈美拉汀治疗抑郁症临床应用专家建议" href="https://www.medsci.cn/guideline/show_article.do?id=2a53f1c0016e30c8" target="_blank" rel="noopener">阿戈美拉汀治疗抑郁症临床应用专家建议</a></li> <li><a title="2018 AAP指南:基层医疗中青少年抑郁症的管理" href="https://www.medsci.cn/guideline/show_article.do?id=19d8b1c0015628c0" target="_blank" rel="noopener">2018 AAP指南:基层医疗中青少年抑郁症的管理</a></li> <li><a title="2017 佛罗里达最佳实践指南:成人抑郁症的药物治疗" href="https://www.medsci.cn/guideline/show_article.do?id=6992d1c001a89662" target="_blank" rel="noopener">2017 佛罗里达最佳实践指南:成人抑郁症的药物治疗</a></li> 更多信息请点击:</ul> </ul> <p><a href="https://www.medsci.cn/guideline/list.do?q=%E6%8A%91%E9%83%81%E7%97%87" target="_blank" rel="noopener">有关抑郁症更多指南</a></p>, tagList=[TagDto(tagId=228, tagName=抑郁症), TagDto(tagId=1113, tagName=药物治疗)], categoryList=[CategoryDto(categoryId=13, categoryName=精神心理科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=23594, appHits=606, showAppHits=12, pcHits=4444, showPcHits=22411, likes=11, shares=24, comments=12, approvalStatus=1, publishedTime=Mon Feb 24 22:59:46 CST 2020, publishedTimeString=2020-01-28, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Feb 24 22:59:46 CST 2020, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 03:39:24 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 日本专家共识:抑郁症的药物治疗.pdf), AttachmentFileName(sort=100, fileName=2020 日本专家共识:抑郁症的药物治疗)])
2020 日本专家共识:抑郁症的药物治疗.pdf
下载请点击:
2020 日本专家共识:抑郁症的药物治疗
下载请点击:
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2099837, encodeId=c4df209983ec0, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/09716af288084795ba128059da55a818/c3137a18601c4c54bb7d71ac97630870.jpg, createdBy=e9985480565, createdName=ozzy, createdTime=Fri Nov 11 10:45:28 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078290, encodeId=707f10e82903d, content=详细, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d7c1341677, createdName=50277, createdTime=Thu Dec 09 07:00:46 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075660, encodeId=969a10e5660a6, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=041c5414352, createdName=ms2000001862732309, createdTime=Wed Dec 01 04:10:44 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997388, encodeId=f3e399e38878, content=有中文的吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eb85544113, createdName=ms5000001821826490, createdTime=Thu Jul 08 06:16:10 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969203, encodeId=b809969203c1, content=謝謝, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a0d2a11691b24091b5b9dbfbadf81dc9/2fdf08a8d767479e869c7752c34716dc.jpg, createdBy=c3915509274, createdName=Ineslou, createdTime=Fri May 28 13:37:58 CST 2021, time=2021-05-28, status=1, ipAttribution=)]
    2022-11-11 ozzy

    非常好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2099837, encodeId=c4df209983ec0, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/09716af288084795ba128059da55a818/c3137a18601c4c54bb7d71ac97630870.jpg, createdBy=e9985480565, createdName=ozzy, createdTime=Fri Nov 11 10:45:28 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078290, encodeId=707f10e82903d, content=详细, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d7c1341677, createdName=50277, createdTime=Thu Dec 09 07:00:46 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075660, encodeId=969a10e5660a6, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=041c5414352, createdName=ms2000001862732309, createdTime=Wed Dec 01 04:10:44 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997388, encodeId=f3e399e38878, content=有中文的吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eb85544113, createdName=ms5000001821826490, createdTime=Thu Jul 08 06:16:10 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969203, encodeId=b809969203c1, content=謝謝, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a0d2a11691b24091b5b9dbfbadf81dc9/2fdf08a8d767479e869c7752c34716dc.jpg, createdBy=c3915509274, createdName=Ineslou, createdTime=Fri May 28 13:37:58 CST 2021, time=2021-05-28, status=1, ipAttribution=)]
    2021-12-09 50277

    详细

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2099837, encodeId=c4df209983ec0, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/09716af288084795ba128059da55a818/c3137a18601c4c54bb7d71ac97630870.jpg, createdBy=e9985480565, createdName=ozzy, createdTime=Fri Nov 11 10:45:28 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078290, encodeId=707f10e82903d, content=详细, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d7c1341677, createdName=50277, createdTime=Thu Dec 09 07:00:46 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075660, encodeId=969a10e5660a6, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=041c5414352, createdName=ms2000001862732309, createdTime=Wed Dec 01 04:10:44 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997388, encodeId=f3e399e38878, content=有中文的吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eb85544113, createdName=ms5000001821826490, createdTime=Thu Jul 08 06:16:10 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969203, encodeId=b809969203c1, content=謝謝, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a0d2a11691b24091b5b9dbfbadf81dc9/2fdf08a8d767479e869c7752c34716dc.jpg, createdBy=c3915509274, createdName=Ineslou, createdTime=Fri May 28 13:37:58 CST 2021, time=2021-05-28, status=1, ipAttribution=)]
    2021-12-01 ms2000001862732309

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2099837, encodeId=c4df209983ec0, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/09716af288084795ba128059da55a818/c3137a18601c4c54bb7d71ac97630870.jpg, createdBy=e9985480565, createdName=ozzy, createdTime=Fri Nov 11 10:45:28 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078290, encodeId=707f10e82903d, content=详细, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d7c1341677, createdName=50277, createdTime=Thu Dec 09 07:00:46 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075660, encodeId=969a10e5660a6, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=041c5414352, createdName=ms2000001862732309, createdTime=Wed Dec 01 04:10:44 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997388, encodeId=f3e399e38878, content=有中文的吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eb85544113, createdName=ms5000001821826490, createdTime=Thu Jul 08 06:16:10 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969203, encodeId=b809969203c1, content=謝謝, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a0d2a11691b24091b5b9dbfbadf81dc9/2fdf08a8d767479e869c7752c34716dc.jpg, createdBy=c3915509274, createdName=Ineslou, createdTime=Fri May 28 13:37:58 CST 2021, time=2021-05-28, status=1, ipAttribution=)]
    2021-07-08 ms5000001821826490

    有中文的吗

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2099837, encodeId=c4df209983ec0, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/09716af288084795ba128059da55a818/c3137a18601c4c54bb7d71ac97630870.jpg, createdBy=e9985480565, createdName=ozzy, createdTime=Fri Nov 11 10:45:28 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078290, encodeId=707f10e82903d, content=详细, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d7c1341677, createdName=50277, createdTime=Thu Dec 09 07:00:46 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075660, encodeId=969a10e5660a6, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=041c5414352, createdName=ms2000001862732309, createdTime=Wed Dec 01 04:10:44 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997388, encodeId=f3e399e38878, content=有中文的吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eb85544113, createdName=ms5000001821826490, createdTime=Thu Jul 08 06:16:10 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969203, encodeId=b809969203c1, content=謝謝, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a0d2a11691b24091b5b9dbfbadf81dc9/2fdf08a8d767479e869c7752c34716dc.jpg, createdBy=c3915509274, createdName=Ineslou, createdTime=Fri May 28 13:37:58 CST 2021, time=2021-05-28, status=1, ipAttribution=)]
    2021-05-28 Ineslou

    謝謝

    0